Next Article in Journal
A Classic Herbal Formula Guizhi Fuling Wan for Menopausal Hot Flushes: From Experimental Findings to Clinical Applications
Previous Article in Journal
Role of Muscarinic Acetylcholine Signaling in Gastrointestinal Cancers
Open AccessArticle

Vindoline—A Natural Product from Catharanthus Roseus Reduces Hyperlipidemia and Renal Pathophysiology in Experimental Type 2 Diabetes

1
Department of Biomedical Sciences, Phytomedicine and Phytochemistry Research Group, Oxidative Stress Research Centre, Faculty of Health & Wellness Sciences, Cape Peninsula University of Technology P.O. Box 1906, Bellville 7535, South Africa
2
Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Windhoek 13388, Namibia
*
Author to whom correspondence should be addressed.
Biomedicines 2019, 7(3), 59; https://doi.org/10.3390/biomedicines7030059
Received: 26 April 2019 / Revised: 21 May 2019 / Accepted: 22 May 2019 / Published: 13 August 2019
(This article belongs to the Section Natural Compounds in Biomedicine)
  |  
PDF [5342 KB, uploaded 21 August 2019]
  |  

Abstract

Cardiovascular diseases (CVDs) and kidney diseases in diabetes are linked to increased mortality and morbidity. The aim of this study was to evaluate the effect of vindoline derived from Catharanthus roseus in diabetes-induced CVDs and kidney disease through assessing inflammation, oxidative stress, hyperlipidaemia and kidney function parameters. Type 2 diabetes was induced in male Wistar rats by 10% fructose water intake for two weeks, followed by a single intraperitoneal injection of 40 mg/kg body weight of streptozotocin (STZ). Six groups (n = 8) of randomly divided rats received vindoline (20 mg/kg) or glibenclamide (5 mg/kg) daily for 6 weeks via oral gavage. Lipid profile markers and markers of atherogenic index were decreased in diabetic rats after treatment with vindoline and glibenclamide. The levels of urea were significantly increased in the diabetic control group (13.66 ± 0.9) compared to the diabetic groups treated with vindoline and glibenclamide (10.62 ± 0.6 and 10.82 ± 0.8), respectively. Vindoline did not significantly alter the levels of inflammatory cytokines; however glibenclamide lowered the levels of TNF-α in kidney and heart tissues. Vindoline improved the ferric reducing antioxidant power in diabetic hearts, while superoxide dismutase (SOD) oxygen radical absorbance capacity was increased in the kidneys. Lipid peroxidation was reduced when compared to the diabetic controls. Vindoline restored the structure of the renal parenchyma and was accompanied by significant decrease in the expression of caspase 9 in diabetic rats when compared to the diabetic controls. View Full-Text
Keywords: cardiovascular diseases; diabetic kidney disease; oxidative stress; inflammation; apoptosis cardiovascular diseases; diabetic kidney disease; oxidative stress; inflammation; apoptosis
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Oguntibeju, O.O.; Aboua, Y.; Goboza, M. Vindoline—A Natural Product from Catharanthus Roseus Reduces Hyperlipidemia and Renal Pathophysiology in Experimental Type 2 Diabetes. Biomedicines 2019, 7, 59.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top